Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials

BMC Psychiatry

Volumn 7, Issue , 2007, Pages

  Derry, Sheena ^a   Andrew, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; TRIAZINE DERIVATIVE;

ADJUVANT THERAPY; AKATHISIA; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MANIA; MEDLINE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; NAUSEA; REMISSION; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; MAJOR DEPRESSION; PREVALENCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; HUMANS; PREVALENCE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZINES;

EID: 35348890745     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-7-40     Document Type: Review

References (65)

1. Swann AC What is bipolar disorder? Am J Psychiatry 2006, 163:177-179 10.1176/appi.ajp.163.2.177 16449465
2. Schaffer A Cairney J Cheung A Veldhuizen S Levitt A Community survey of bipolar disorder in Canada: Lifetime prevalence and illness characteristics Can J Psychiatry 2006, 51:9-16 16491979
3. Grant BF Stinson FS Hasin DS Dawson DA Chou SP Ruan WJ Huang B Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions J Clin Psychiatry 2005, 66:1205-1215 16259532
4. Perlis RH Ostacher MJ Patel JK Marangell LB Zhang H Wisniewski SR Ketter TA Miklowitz DJ Otto MW Gyulai L Reilly-Harrington NA Nierenberg AA Sachs GS Thase ME Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Am J Psychiatry 2006, 163:217-224 10.1176/ appi.ajp.163.2.217 16449474
5. Bagnall AM Jones L Ginnelly L Lewis R Glanville J Gilbody S Davies L Torgerson D Kleijnen J A systematic review of atypical antipsychotic drugs in schizophrenia Health Technol Assess 2003, 7:1-193 12925268
6. Lee PE Gill SS Freedman M Bronskill SE Hillmer MP Rochon PA Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: Systematic review BMJ 2004, 329:75 449807 15194601 10.1136/bmj.38125.465579.55
7. Jadad AR Moore RA Carroll D Jenkinson C Reynolds DJ Gavaghan DJ McQuay HJ Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996, 17:1-12 10.1016/ 0197-2456(95)00134-4 8721797
8. Moher D Cook DJ Eastwood S Olkin I Rennie D Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses Lancet 1999, 354:1896-1900 10.1016/S0140-6736(99)04149-5 10584742
9. Moore RA Gavaghan D Tramer MR Collins SL McQuay HJ Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects Pain 1998, 78:209-216 10.1016/S0304-3959(98)00140-7 9870574
10. Gavaghan DJ Moore RA McQuay HJ An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data Pain 2000, 85:415-424 10.1016/S0304-3959(99)00302-4 10781914
11. Sterne JA Gavaghan D Egger M Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature J Clin Epidemiol 2000, 53:1119-1129 10.1016/ S0895-4356(00)00242-0 11106885
12. Terrin N Schmid CH Lau J In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias J Clin Epidemiol 2005, 58:894-901 10.1016/j.jclinepi.2005.01.006 16085192
13. L'Abbe KA Detsky AS O'Rourke K Meta-analysis in clinical research Ann Intern Med 1987, 107:224-233 3300460
14. Morris JA Gardner MJ Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates Statistics with confidence - confidence intervals and statistical guidelines London: British Medical Journal Gardner MJ, Altman DG 1995:50-63
15. Cook RJ Sackett DL The number needed to treat: A clinically useful measure of treatment effect BMJ 1995, 310:452-454 7873954
16. Tramèr MR Reynolds DJM Moore RA McQuay HJ Impact of covert duplicate publication on meta-analysis: A case study British Medical Journal 1997, 315:635-9 9310564
17. Moore RA Derry S Makinson GT McQuay HJ Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports Arthritis Res Ther 2005, 7:R644-65 1174947 15899051 10.1186/ar1704
18. Tohen M Vieta E Calabrese J Ketter TA Sachs G Bowden C Mitchell PB Centorrino F Risser R Baker RW Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch Gen Psychiatry 2003, 60:1079-1088 10.1001/ archpsyc.60.11.1079 14609883
19. Shelton RC Stahl SM Risperidone and paroxetine given singly and in combination for bipolar depression J Clin Psychiatry 2004, 65:1715-1719 15641878
20. Calabrese JR Keck PE Jr Macfadden W Minkwitz M Ketter TA Weisler RH Cutler AJ McCoy R Wilson E Mullen J A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am J Psychiatry 2005, 162:1351-1360 10.1176/ appi.ajp.162.7.1351 15994719
21. Brown EB McElroy SL Keck PE Jr Deldar A Adams DH Tohen M Williamson DJ A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression J Clin Psychiatry 2006, 67:1025-1033 16889444
22. Thase ME Macfadden W Weisler RH Chang W Paulsson B Khan A Calabrese JR BOLDER II Study Group Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study) J Clin Psychopharmacol 2006, 26:600-609 10.1097/ 01.jcp.0000248603.76231.b7 17110817
23. Segal J Berk M Brook S Risperidone compared with both lithium and haloperidol in mania: A double-blind, randomized controlled trial Clin Neuropharmacol 1998, 21:176-180 9617509
24. Tohen M Sanger TM McElroy SL Tollefson GD Chengappa KN Daniel DG Petty F Centorrino F Wang R Grundy SL Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group Am J Psychiatry 1999, 156:702-709 10327902
25. Berk M Ichim L Brook S Olanzapine compared to lithium in mania: A double-blind randomized controlled trial Int Clin Psychopharmacol 1999, 14:339-343 10.1097/00004850-199911000-00003 10565800
26. Tohen M Jacobs TG Grundy SL McElroy SL Banov MC Janicak PG Sanger T Risser R Zhang F Toma V Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group Arch Gen Psychiatry 2000, 57:841-849 10.1001/archpsyc.57.9.841 10986547
27. Tohen M Baker RW Altshuler LL Zarate CA Suppes T Ketter TA Milton DR Risser R Gilmore JA Breier A Olanzapine versus divalproex in the treatment of acute mania Am J Psychiatry 2002, 159:1011-1017 10.1176/ appi.ajp.159.6.1011 12042191
28. Hirschfeld RM Keck PE Jr Kramer M Karcher K Canuso C Eerdekens M Grossman F Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial Am J Psychiatry 2004, 161:1057-1065 10.1176/appi.ajp.161.6.1057 15169694
29. Yatham LN Grossman F Augustyns I Vieta E Ravindran A Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial Br J Psychiatry 2003, 182:141-147 10.1192/bjp.182.2.141 12562742
30. Sachs GS Grossman F Ghaemi SN Okamoto A Bowden CL Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety Am J Psychiatry 2002, 159:1146-1154 10.1176/appi.ajp.159.7.1146 12091192
31. Sachs G Chengappa KN Suppes T Mullen JA Brecher M Devine NA Sweitzer DE Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study Bipolar Disord 2004, 6:213-223 10.1111/j.1399-5618.2004.00115.x 15117400
32. Yatham LN Paulsson B Mullen J Vagero AM Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania J Clin Psychopharmacol 2004, 24:599-606 10.1097/ 01.jcp.0000144887.66319.2f 15538120
33. Keck PE Jr Versiani M Potkin S West SA Giller E Ice K Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial Am J Psychiatry 2003, 160:741-748 10.1176/ appi.ajp.160.4.741 12668364
34. Keck PE Jr Marcus R Tourkodimitris S Ali M Liebeskind A Saha A Ingenito G A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania Am J Psychiatry 2003, 160:1651-1658 10.1176/appi.ajp.160.9.1651 12944341
35. Potkin SG Keck PE Jr Segal S Ice K English P Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial J Clin Psychopharmacol 2005, 25:301-310 10.1097/ 01.jcp.0000169068.34322.70 16012271
36. Khanna S Vieta E Lyons B Grossman F Eerdekens M Kramer M Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study Br J Psychiatry 2005, 187:229-234 10.1192/bjp.187.3.229 16135859
37. Smulevich AB Khanna S Eerdekens M Karcher K Kramer M Grossman F Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol Eur Neuropsychopharmacol 2005, 15:75-84 10.1016/j.euroneuro.2004.06.003 15572276
38. Sachs G Sanchez R Marcus R Stock E McQuade R Carson W Abou-Gharbia N Impellizzeri C Kaplita S Rollin L Iwamoto T Aripiprazole Study Group Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study J Psychopharmacol 2006, 20:536-546 10.1177/0269881106059693 16401666
39. Tohen M Chengappa KN Suppes T Zarate CA Jr Calabrese JR Bowden CL Sachs GS Kupfer DJ Baker RW Risser RC Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy Arch Gen Psychiatry 2002, 59:62-69 10.1001/archpsyc.59.1.62 11779284
40. Zajecka JM Weisler R Sachs G Swann AC Wozniak P Sommerville KW A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder J Clin Psychiatry 2002, 63:1148-1155 12523875
41. Tohen M Goldberg JF Gonzalez-Pinto Arrillaga AM Azorin JM Vieta E Hardy-Bayle MC Lawson WB Emsley RA Zhang F Baker RW A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania Arch Gen Psychiatry 2003, 60:1218-1226 10.1001/ archpsyc.60.12.1218 14662554
42. Bowden CL Grunze H Mullen J Brecher M Paulsson B Jones M Vagero M Svensson K A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder J Clin Psychiatry 2005, 66:111-121 15669897
43. McIntyre RS Brecher M Paulsson B Huizar K Mullen J Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial Eur Neuropsychopharmacol 2005, 15:573-585 10.1016/j.euroneuro.2005.02.006 16139175
44. Vieta E Bourin M Sanchez R Marcus R Stock E McQuade R Carson W Abou-Gharbia N Swanink R Iwamoto T Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial Br J Psychiatry 2005, 187:235-242 10.1192/ bjp.187.3.235 16135860
45. Tohen M Ketter TA Zarate CA Suppes T Frye M Altshuler L Zajecka J Schuh LM Risser RC Brown E Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study Am J Psychiatry 2003, 160:1263-1271 10.1176/appi.ajp.160.7.1263 12832240
46. Tohen M Chengappa KN Suppes T Baker RW Zarate CA Bowden CL Sachs GS Kupfer DJ Ghaemi SN Feldman PD Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone Br J Psychiatry 2004, 184:337-345 10.1192/bjp.184.4.337 15056579
47. Tohen M Greil W Calabrese JR Sachs GS Yatham LN Oerlinghausen BM Koukopoulos A Cassano GB Grunze H Licht RW Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial Am J Psychiatry 2005, 162:1281-1290 10.1176/appi.ajp.162.7.1281 15994710
48. Tohen M Calabrese JR Sachs GS Banov MD Detke HC Risser R Baker RW Chou JC Bowden CL Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine Am J Psychiatry 2006, 163:247-256 10.1176/appi.ajp.163.2.247 16449478
49. Keck PE Jr Calabrese JR McQuade RD Carson WH Carlson BX Rollin LM Marcus RN Sanchez R Aripiprazole Study Group A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder J Clin Psychiatry 2006, 67:626-37 16669728
50. Ioannidis JP Why most published research findings are false PLoS Med 2005, 2:e124 1182327 16060722 10.1371/journal.pmed.0020124
51. Moher D Pham B Jones A Cook DJ Jadad AR Moher M Tugwell P Klassen TP Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998, 352:609-613 10.1016/S0140-6736(98)01085-X 9746022
52. Khan KS Daya S Jadad A The importance of quality of primary studies in producing unbiased systematic reviews Arch Intern Med 1996, 156:661-666 10.1001/archinte.156.6.661 8629879
53. Schulz KF Subverting randomization in controlled trials JAMA 1995, 274:1456-1458 10.1001/jama.274.18.1456 7474192
54. Perlis RH Welge JA Vornik LA Hirschfeld RM Keck PE Jr Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials J Clin Psychiatry 2006, 67:509-516 16669715
55. Rendell JM Gijsman HJ Keck P Goodwin GM Geddes JR Olanzapine alone or in combination for acute mainia Cochrane Database Syst Rev 2003, 3:CD004040 12918000
56. Rendell JM Gijsman HJ Bauer MS Goodwin GM Geddes GR Risperidone alone or in combination for acute mania Cochrane Database Syst Rev 2006, 1:CD004043 16437472
57. Smith LA Cornelius V Warnock A Tacchi MJ Taylor D Acute bipolar mania: A systematic review and meta-analysis of co-therapy vs. monotherapy Acta Psychiatr Scand 2007, 115:12-20 10.1111/j.1600-0447.2006.00912.x 17201861
58. Scherk H Pajonk FG Leucht S Second-generation antipsychotic agents in the treatment of acute mania: A systematic review and meta-analysis of randomized controlled trials Arch Gen Psychiatry 2007, 64:442-455 10.1001/archpsyc.64.4.442 17404121
59. Gao K Gajwani P Elhaj O Calabrese JR Typical and atypical antipsychotics in bipolar depression J Clin Psychiatry 2005, 66:1376-1385 16420074
60. Muzina DJ Calabrese JR Maintenance therapies in bipolar disorder: Focus on randomized controlled trials Aust N Z J Psychiatry 2005, 39:652-661 10.1111/j.1440-1614.2005.01649.x 16050919
61. McQuay H Carroll D Moore A Variation in the placebo effect in randomised controlled trials of analgesics: All is as blind as it seems Pain 1996, 64:331-335 10.1016/0304-3959(95)00116-6 8740611
62. Moore RA Edwards JE McQuay HJ Sildenafil (Viagra) for male erectile dysfunction: A meta-analysis of clinical trial reports BMC Urol 2002, 2:6 115867 12049673 10.1186/1471-2490-2-6
63. Edwards JE McQuay HJ Moore RA Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials Pain 2004, 111:286-296 10.1016/ j.pain.2004.07.004 15363872
64. Moore RA Derry S Makinson GT McQuay HJ Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports Arthritis Res Ther 2005, 7:R644-65 Erratum in: Arthritis Res Ther 2006, 8:401. 1174947 15899051 10.1186/ ar1704
65. Chengappa KN Hennen J Baldessarini RJ Kupfer DJ Yatham LN Gershon S Baker RW Tohen M Recovery and functional outcomes following olanzapine treatment for bipolar I mania Bipolar Disord 2005, 7:68-76 10.1111/ j.1399-5618.2004.00171.x 15654934